Webinars and Sponsored Roundtables — Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Product Spotlight

QuidelOrtho

VITROS 3600 Immunodiagnostic System

Company

QuidelOrtho

Name of instrument

VITROS 3600 Immunodiagnostic System

Contact

Laura Osborne  

Email

laura.osborne@quidelortho.com

City, State

Raritan, NJ

Phone

800-828-6316   

Website

http://www.quidelortho.com

Type of instrument

immunoassay

List price/First year sold in U.S.

—/2008

Targeted hospital bed size/Targeted test volume

150–4,500/daily: > 200; monthly: > 5,000; annual: > 60,000

Company manufactures instrument

no (manufactured by Nypro Engineering and Technology group service; also sold by Cardinal, McKesson, more)

Other models in this family of analyzers

VITROS ECi/ECiQ Immunodiagnostic System

No. of units in clinical use in U.S./Outside U.S. (countries)

> 150/> 690 (North, Central, and South America, more)

Dimensions (H × W × D)/Instrument footprint

65 × 84 × 35 in./19.4 sq. ft.

Weight empty/Weight fully loaded

1,740 lbs./—

No. of different measured assays onboard simultaneously

31 (31 can be run and calibrated at one time)

No. of user-definable (open chemistry) channels

0

Test throughput per hour/Assay run time

189/16–73 min. (avg. 30 min.)

No. of direct ion-selective electrode channels

—

Detection methods

—

Stat time until completion/specimen throughput for Ion-selective electrode

—

Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel

—

Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel

—

Typical time delay from ordering stat test until aspiration of sample

—

Fully automated microplate immunoassay system

no

Methodologies supported

chemiluminescence, enzyme immunoassay, direct enhanced chemiluminescence

Separation methodologies

coated microwell

Stat time until completion of a ß-hCG test

24 min.

Stat time until completion of a cTn test

18 min.

• Typical time delay from test order to aspiration of sample

1 min.

Reagents refrigerated onboard/Reagents ready to use

yes (10°C)/yes

Reagent lot tracking/Reagent inventory

yes/yes

Reagent form/Reagents barcoded

— (closed reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/no

Walkaway capability/Walkaway duration

yes/120 min. or 90 specimens or 3,100 tests

Design of sample-handling system

circular routine sampling center

Uses washable cuvettes/Uses disposable cuvettes

no/no

Min.–max. sample volume that can be aspirated at one time 

2–200 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

—/10 µL/35 µL

Dedicated pediatric sample cup

yes (dead volume: 35 µL)

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/yes (micro sample cups, 10.25 × 45 mm, 12 × 75 mm, 12 × 100 mm, 13 × 75 mm, 13 × 100 mm, 16 × 75 mm, 16 × 100 mm)

Pierces caps on primary tubes

no

Protects against probe collision

yes

Detects clots/liquid level/short sample

yes/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

detection and quantitation for hemolysis, icterus, lipemia; detection for clots

Dilutes patient samples onboard/Susceptibility to carryover

yes (can be programmed to perform dilutions prior to analysis)/0

Automatic rerun capability

yes

Sample volume can be diluted to rerun out-of-linear-range high results

yes

Sample volume can be concentrated to rerun out-of-linear-range low results

no

Autocalibration/Multipoint calibration supported

no (calibrants are not stored onboard)/yes (recommended avg. frequency: 28 days)

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

—/—/—/—/28 days

Automatic programmable start/Automatic programmable shutdown

no/no

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

yes

Waste management

manually by user

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128, ISBT 128)/yes

Lab can control analyzer from remote computer

no

Instrument can diagnose its own malfunctions

yes (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

yes

Data-management capability/LIS or EHR systems interfaced

onboard/—

LIS interface provided/Bidirectional interface capability

yes (additional cost)/yes (broadcast download and host query)

Modem servicing provided/Service engineer on-site response time

yes/4 hrs.

Mean time between failures

— (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

daily: < 10 min.; weekly: 30 min.; monthly: 20 min.

Maintenance records kept onboard for user/vendor

yes (includes audit trail of who replaced parts)/no

Maintenance training demonstration module onboard

yes

Training included with purchase/Avg. time for basic user training

yes (2 training slots)/5 days (at customer site)

Advanced operator training/Extra charge for follow-up or advanced training

yes (at customer site)/yes

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/depends on plan selected

Distinguishing features (supplied by company)

Intellicheck technology reports on diagnostic checks throughout the testing process to minimize errors for consistent performance; designed to use single-patient consumables without the need for water, eliminating risk of carryover; MicroSensor technology automates detection of HIL interferences

More products
in this guide

Alinity ci-series
ASI Evolution RPR Syphilis Analyzer
DxI 9000 Access Immunoassay Analyzer
Pictus 700 (P700)
Agility Automated ELISA System
AIX1000 Agglutination Instrument
Yumizen C1200
Yumizen C560
VITROS 4600 Chemistry System
VITROS XT 7600 Integrated System
cobas pro integrated solutions
dIFine P30 Processor
IMMULITE 2000 XPi Immunoassay System
Phadia 250 Laboratory System
B⋅R⋅A⋅H⋅M⋅S KRYPTOR GOLD
QUANTA-Lyser 3000